All In Biotech

Drug Trial Radar · NCT07210723

A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 332 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

332

Planned (sponsor's estimate)

Start

Feb 13, 2026

Primary completion

Sep 2027

Study completion Jan 2028

Sponsor

Lead sponsor
Kardigan, Inc.Industry
Sponsor type
Industry
First posted
Oct 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Sponsor is studying an investigational medication called danicamtiv to determine if it can help people with genetic and familial dilated cardiomyopathy (DCM). Investigational means that the safety and effectiveness of danicamtiv have not been established. Currently, there are no approved drugs that are designed specifically to treat genetic or familial DCM. The purpose of this study is to evaluate how well danicamtiv works compared to a placebo (sugar pill that looks like danicamtiv pill but does not contain any danicamtiv) and see how safe it is for people with genetic and familial DCM. In DCM, the heart muscle weakens and enlarges, making it harder for the heart to pump blood; this can happen for different reasons. Some people have DCM because of a change in a gene (called genetic DCM). Others may have DCM that runs in their family, even if no specific gene change is found (called familial DCM). The main goals of the study are: * To assess the effect of danicamtiv on cardiac function using echocardiogram. * To evaluate the impact of danicamtiv on exercise capacity * To evaluate the safety and tolerability of danicamtiv Participants will: * Take danicamtiv or placebo every day for approximately 6 months * Visit the clinic about 12 times for initial evaluation, checkups, tests and follow up

Conditions

  • Symptomatic Genetic Dilated Cardiomyopathy

Interventions

  • danicamtivDrug

    Danicamtiv will be administrated twice daily for up to 26 weeks

  • PlaceboDrug

    Placebo will be administrated twice daily for up to 26 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Change from Baseline (Day 1) to Week 26 in left atrial function index in Cohort 1Time frame: 26 weeks
  2. Part 2: Change from Baseline (Day 1) to Week 26 in peak VO2 in Cohort 1Time frame: 26 weeks

Locations

79 sites in 11 countries. Site status is shown where the registry gives one.

  • University of Alabama Birmingham

    Birmingham, Alabama · Recruiting

  • Cedars Sinai

    Los Angeles, California · Recruiting

  • University of California, Los Angeles (UCLA) - David Geffen School of Medicine

    Los Angeles, California · Not yet recruiting

  • University of California, San Diego (UCSD) - Medical Center

    San Diego, California · Recruiting

  • UCSF

    San Francisco, California · Recruiting

  • Stanford University Medical Center

    Stanford, California · Recruiting

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbia · Recruiting

  • Mayo Clinic - Jacksonville

    Jacksonville, Florida · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • Louisiana State University (LSU) Health Sciences Center

    New Orleans, Louisiana · Recruiting

  • Johns Hopkins Medicine

    Baltimore, Maryland · Recruiting

  • Brigham and Women's Hospital

    Boston, Massachusetts · Recruiting

  • Henry Ford Health System

    Detroit, Michigan · Recruiting

  • University of Minnesota

    Minneapolis, Minnesota · Recruiting

  • Mayo Clinic Rochester

    Rochester, Minnesota · Recruiting

  • Saint Luke's Mid America Heart Institute

    Kansas City, Missouri · Recruiting

  • Washington University in St. Louis

    St Louis, Missouri · Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • NYU Langone Health

    New York, New York · Recruiting

  • Columbia University Medical Center/ New York Presbyterian Hospital

    New York, New York · Recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • The Lindner Center for Research and Education at The Christ Hospital

    Cincinnati, Ohio · Recruiting

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio · Recruiting

  • Oregon Health & Science University (OHSU)

    Portland, Oregon · Recruiting

  • University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

  • Baylor College of Medicine

    Houston, Texas · Recruiting

  • Houston Methodist Hospital

    Houston, Texas · Recruiting

  • AZORG - Campus Moorselbaan

    Aalst, Belgium · Recruiting

  • Universite Libre de Bruxelles (ULB) - Hopital Erasme

    Brussels, Belgium · Recruiting

  • Universitair Ziekenhuis Antwerpen (UZA)

    Edegem, Belgium · Recruiting

  • Jessa Ziekenhuis

    Hasselt, Belgium · Recruiting

  • UZ Leuven

    Leuven, Belgium · Recruiting

  • Aarhus University Hospital

    Aarhus, Denmark · Recruiting

  • Rigshospitalet

    Copenhagen, Denmark · Recruiting

  • Odense University Hospital - Odense

    Odense, Denmark · Recruiting

  • CHRU de Tours - Hopital Trousseau

    Chambray-lès-Tours, France · Recruiting

  • CHU de Lille - Institut Coeur Poumon

    Lille, France · Not yet recruiting

  • AP-HP Hopital Pitie-Salpetriere

    Paris, France · Recruiting

  • AP-HP Hopital Europeen Georges Pompidou

    Paris, France · Recruiting

Showing 40 of 79 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.